- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01160848
Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
A Clinical Study of Photoactive Porphyrins (PAP) Levels in Acne-affected Skin After Topical Visonac Application in Patients With Moderate to Severe Facial Acne Vulgaris
Open, prospective, randomized, single-centre study in patients with moderate to severe facial acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4 inflammatory lesions, will be selected in acne-affected areas in the face. One area should be identified on each cheek and one area should be identified on the forehead. The minimum distance between the three areas should be at least 4 cm. For each patient the three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application. After the last fluorescence spectroscopy reading, the cream should be wiped off and the patient should protect the three areas from sunlight, prolonged, or intense light for 2 days.
The study was extended with additionally 8 patients to explore the photoactive porphyrin levels over a 24 hour period:
The patients will clean their face with Cetaphil Gentle Skin Cleanser before cream application. For each patient the three areas will be randomized to Visonac 80mg left on the skin for 24 hours and Visonac (MAL8%) to be wiped of after 1 hour.
In vivo fluorescence spectroscopy will be performed at all three areas before cream application, and at 2h, 3 h, 4h, 5h, 8h, 10h, 11h, 12h, 13h, 15 and 24h after cream application. The exact time points may be adjusted based on the result from the previously included patients. All patients will be instructed to protect the three areas from sunlight, prolonged, or intense light for 2 days.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Area cleaned with saline water and occluded with Tegaderm
- Drug: Area cleaned with saline water
- Drug: Area cleaned with Ethyl alcohol solution
- Drug: Visonac left on the skin for 24 hours in facial area one
- Drug: Visonac wiped off after one hour
- Drug: Visonac left on the skin 24 hours in facial area two
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78759
- Dermresearch, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and verified informed consent form. For patients under age of 18, an assent form in conjunction with an informed consent form, signed and verified by parent/guardian.
- Adolescent and adult female and male patients, from 12 to 35 years of age.
- Patients with moderate to severe facial acne vulgaris according to the IGA scale.
- Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to the study visit.
- Patients with skin type II to III (Fitzpatrick).
- Patients with 3 areas of 4 cm in diameter, each including at least with at least 4 inflammatory lesions (papules, pustules, and nodules) in the face (at cheek and forehead).
Exclusion Criteria:
- Subject is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- Patients unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g. drug or alcohol abuse).
- Female subjects with childbearing potential (i.e. ovulation, pre-menopausal, not surgically sterilized) not willing to use a medically accepted contraceptive regimen while on treatment.
- Pregnancy
- Lactating.
- Participation in other clinical studies either currently or within the last 30 days.
- Patients with porphyria.
- Known allergy to (MAL), to a similar PDT compound, or to excipients of the cream
- Patients with cutaneous photosensitivity.
- Patients that have received topical treatments for their acne within the last 14 days. Medicated cleansers not containing active ingredients such as 5% BPO or high concentration of salicylic acid may be stopped before the treatment. (Cosmetic Cleansers that contains no more than 2 % salicylic acid is allowed).
- Patients that has received oral antibiotics for treatment of their acne within the last month.
- Patients that has received oral isotretinoin within the last 6 months.
- Patients with a beard that might interfere with study assessments.
- Patients with melanoma or dysplastic nevi in the treatment area
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Part 1
Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream.
One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time.
In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
|
|
Other: Part 2
For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Photoactive Porphyrins Level
Time Frame: 1.5 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy
|
1.5 hours after cream application
|
Photoactive Porphyrins Level
Time Frame: 3 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy
|
3 hours after cream application
|
Photoactive Porphyrins Level
Time Frame: 3 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy
|
3 hours after cream application
|
Photoactive Porphyrins Level
Time Frame: 8 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy
|
8 hours after cream application
|
Photoactive Porphyrins Level
Time Frame: 12 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy
|
12 hours after cream application
|
Photoactive Porphyrins Level
Time Frame: 24 hours after cream application
|
Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy
|
24 hours after cream application
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael T. Jarratt, M.D., Derm Research, PLLC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PC TA205/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
-
Assiut UniversityCompleted
Clinical Trials on Area cleaned with saline water and occluded with Tegaderm
-
Centers for Disease Control and PreventionProcter and Gamble; Health Oriented Preventive EducationCompleted
-
Ministry of Health, RwandaCompletedOdor Levels of Study ArmsRwanda
-
Patan Academy of Health SciencesNot yet recruiting
-
Ryerson UniversityMount Saint Vincent UniversityCompleted
-
Chulalongkorn UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
U.S. Army Medical Research and Development CommandCompletedOld World Cutaneous LeishmaniasisTunisia
-
International Centre for Diarrhoeal Disease Research...University of California, Berkeley; University of Maryland; Harvard UniversityCompletedDevelop a New Group Version of the Becker-DeGroot-Marsckek (BDM) Auction to Measure Willingness to Pay of Compound Members for Shared Hardware. | Develop a New Survey Instrument to Measure Behavioural Determinants of Hand Washing and Water Treatment Like Disgust and Shame or Social... and other conditionsBangladesh
-
University of TorontoCanadian Institutes of Health Research (CIHR)Completed